Log in to search using one of your social media accounts:

 

New Data for Pradaxa ® and Praxbind® at AHA Scientific Sessions 2017
New Data for Pradaxa ® and Praxbind® at AHA Scientific Sessions 2017 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
Pradaxa ®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ®
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® data to be presented at the ESC Congress 2014
New Pradaxa ® data to be presented at the ESC Congress 2014 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) Video Statement
Pradaxa ® (dabigatran etexilate) Video Statement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New publication in The Lancet describes effective reversal of Pradaxa ® in healthy volunteers
New publication in The Lancet describes effective reversal of Pradaxa ® in healthy volunteers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim Presents New idarucizumab (Praxbind ®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
Boehringer Ingelheim Presents New idarucizumab (Praxbind ®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa ® in Routine Clinical Care
Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa ® in Routine Clinical Care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Praxbind ® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
Praxbind ® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New efficacy and safety data for Pradaxa ® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013
New efficacy and safety data for Pradaxa ® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® safety and efficacy data to be featured at ‘Best of ASH’ session
New Pradaxa ® safety and efficacy data to be featured at ‘Best of ASH’ session (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Treatment with Pradaxa ® associated with better patient outcomes after a major bleeding event compared to warfarin
Treatment with Pradaxa ® associated with better patient outcomes after a major bleeding event compared to warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
Pradaxa ® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Wealth of worldwide evidence on Pradaxa ® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions
Wealth of worldwide evidence on Pradaxa ® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations
Pradaxa ® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA and EMA reaffirm important health benefits and safety of Pradaxa ® (dabigatran etexilate) for patients with atrial fibrillation
FDA and EMA reaffirm important health benefits and safety of Pradaxa ® (dabigatran etexilate) for patients with atrial fibrillation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session
New Pradaxa ® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA approves Pradaxa ® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
FDA approves Pradaxa ® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Positive CHMP opinion for Pradaxa ® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots
Positive CHMP opinion for Pradaxa ® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New findings from two studies support substantial benefit of Pradaxa ® for prevention of recurrent deep vein thrombosis and pulmonary embolism
New findings from two studies support substantial benefit of Pradaxa ® for prevention of recurrent deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa ® compared to warfarin
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa ® compared to warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA perspective published in the  New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
FDA perspective published in the  New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa ® beyond 6 years
New long-term treatment data confirms consistent benefit and safety profile of Pradaxa ® beyond 6 years (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa ® (dabigatran etexilate) in expanded patient populations
Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa ® (dabigatran etexilate) in expanded patient populations (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do
Pradaxa ® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New long-term data reinforce safety profile of Pradaxa ® for stroke prevention in AF
New long-term data reinforce safety profile of Pradaxa ® for stroke prevention in AF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data analyses show consistent efficacy and safety profile of Pradaxa ® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
New data analyses show consistent efficacy and safety profile of Pradaxa ® in broad range of patients with acute deep vein thrombosis or pulmonary embolism* (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa ® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
Application submitted to the European Medicines Agency (EMA) for use of Pradaxa ® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

As the benefits and safety of Pradaxa ® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients
As the benefits and safety of Pradaxa ® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Antidote for rapid reversal of Pradaxa ® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
Antidote for rapid reversal of Pradaxa ® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism
New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Benefits of Pradaxa ® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
Benefits of Pradaxa ® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa ® (dabigatran etexilate) litigation
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa ® (dabigatran etexilate) litigation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Pradaxa ® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
Pradaxa ® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
New Pradaxa ® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ® (dabigatran etexilate) specific investigational antidote
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ® (dabigatran etexilate) specific investigational antidote (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Efficacy and Safety Profile of Pradaxa ® (dabigatran etexilate) Repeatedly Confirmed
Efficacy and Safety Profile of Pradaxa ® (dabigatran etexilate) Repeatedly Confirmed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Pradaxa ® data to be presented at the ESC Congress 2014
New Pradaxa ® data to be presented at the ESC Congress 2014 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Extensive experience in clinical practice and expanding research programme support use of Pradaxa ® for clot prevention
Extensive experience in clinical practice and expanding research programme support use of Pradaxa ® for clot prevention (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa ® on kidney function over time compared to warfarin
ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa ® on kidney function over time compared to warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa ® than with warfarin
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa ® than with warfarin (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement
Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

NOACs Show Lower Risk of Adverse Renal Outcomes in A - Fib
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 21, 2017 Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

New RE-DUAL PCI Data: Dabigatran Dual Therapy Benefit Consistent New RE-DUAL PCI Data: Dabigatran Dual Therapy Benefit Consistent
The"reassuring" findings from the RE-DUAL PCI study were seen in several subgroups of patients with atrial fibrillation in a setting where they face an excess risk of bleeding with current triple antithrombotic therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 17, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

New Data for Pradaxa < sup > ® < /sup > and Praxbind < sup > ® < /sup > at AHA Scientific Sessions 2017
New Data for Pradaxa® and Praxbind® at AHA Scientific Sessions 2017 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 10, 2017 Category: Research Source Type: news

Despite 'bad press,' new blood thinners aren't linked to greater bleeding risk: Study
New anti-clotting drugs -- like Xarelto, Pradaxa and Eliquis -- aren't linked with a higher risk of bleeding than the older drug warfarin, a new study finds (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 18, 2017 Category: Consumer Health News Source Type: news